French Registry of First-line Treatment of Acute Promyelocytic Leukemia
NCT ID: NCT02938858
Last Updated: 2025-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
400 participants
OBSERVATIONAL
2015-10-31
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital
NCT05558943
A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)
NCT00591526
Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
NCT03588078
RWE of 1st Line Treatment With ATO/ATRA for Adult APL
NCT04897490
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
NCT02688140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Documentation of clinical and biologic effectiveness of the two first-line treatment approaches available for non-high-risk APL patients.
* Documentation of Minimal Residual Disease (MRD).
* Correlation of clinical outcomes with the chosen therapy.
* Validation of published prognostic factors and identification of new prognostic factors
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ATRA-chimio
according to usual practice center
No interventions assigned to this group
ATRA-ATO
according to usual practice center
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-high-risk APL (White Blood Count \< 10000/μl at presentation)
* Age ≤ 70 years
Exclusion Criteria
* Newly-diagnosed High-risk APL (White Blood Count \> 10000/μl at presentation)
* Age \> 70 years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Groupe Francophone des Myelodysplasies
OTHER
Teva Pharmaceuticals USA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre FENAUX, MD
Role: PRINCIPAL_INVESTIGATOR
French APL Cooperative Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier d'Aix en Provence
Aix-en-Provence, , France
Groupe Hospitalier SUD
Amiens, , France
Centre Hospitalier V. Dupouy
Argenteuil, , France
Hôpital Jean Minjoz
Besançon, , France
CHU Bordeaux Pellegrin enfant
Bordeaux, , France
CHRU de Brest - Pédiatrie Spécialisée
Brest, , France
CHU Estaing
Clermont-Ferrand, , France
Hôpital Henri Mondor
Créteil, , France
CHU de Grenoble
Grenoble, , France
Hopital Andre Mignot
Le Chesnay, , France
CH Dr Schaffner
Lens, , France
Chru - Hopital Claude Huriez
Lille, , France
Hôpital universitaire Dupuytren
Limoges, , France
Institut Paoli Calmettes
Marseille, , France
Chu Timone
Marseille, , France
CHR Metz-Thionville - Hôpital de Marcy
Metz, , France
CHU Saint Eloi
Montpellier, , France
CHU Hôtel Dieu
Nantes, , France
Hôpital de la Source
Orléans, , France
Hôpital TROUSSEAU
Paris, , France
Hôpital Necker
Paris, , France
Hôpital Robert Debré
Paris, , France
CHU Hôpital Sud - service Hémato-oncologie Pédiatrique
Rennes, , France
Hôpital V. Provo
Roubaix, , France
Centre Henri Becquerel
Rouen, , France
Institut de Cancerologie de La Loire
Saint-Priest-en-Jarez, , France
IUCT Oncopole
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
French registry APL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.